Skip to main content
SpringerLink
Log in

Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the United States. Traditionally, warfarin has been used to prevent the occurrence of stroke in intermediate-to-high risk patients. Target-specific oral anticoagulants (TSOACs) have become a favorable alternative; however, recommendations for differentiating between the available TSOACs were lacking within the 2012 CHEST guidelines. The objective of this retrospective, observational study was to identify current anticoagulation prescribing habits in patients admitted with new-onset AF, and evaluate the appropriateness of discharge therapy based on national guidelines. Additionally, a practice guideline was created for use at our institution to stratify appropriate use of TSOACs. Patients were included if they were at least 18 years old and were admitted with a primary diagnosis of new-onset, non-valvular AF between July 1, 2012 and June 30, 2013. CHADS2, CHA2DS2VASc, and HAS-BLED scores were calculated based on patient data. Between July 2012 and June 2013, 143 patients were included in the study. The average CHADS2 score was 1.7, the average CHA2DS2VASc score was 3.0, and the average HAS-BLED score was 2.4. The use of no antithrombotics decreased as the CHA2DS2VASc score increased, aspirin use stayed consistent across risk groups, warfarin use increased as the CHA2DS2VASc score increased, and TSOAC use decreased with increasing CHA2DS2VASc score. A total of 34 % of study patients were prescribed inappropriate treatment upon discharge, based on national guidelines. This study demonstrated that patients admitted to our hospital were prescribed appropriate therapy the majority of the time; however, 34 % were prescribed inadequate antithrombotic therapy compared to current practice guidelines given their CHA2DS2VASc score. The development of an institution-specific guideline stratifying appropriate use of anticoagulation in this population may increase adherence to national guideline recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sellers MB, Newby LK (2011) Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J 161:241–246

    Article  PubMed  Google Scholar 

  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 17(361):1139–1151

    Article  Google Scholar 

  3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S; ARISTOTLE Committees and Investigators et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  5. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY (2012) Antithrombotic therapy for atrial fibrillation—antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(suppl):e531S–e575S

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2011) Validation of clinical classification schemes for predicting stroke—results from the national registry of atrial fibrillation. JAMA 285:2864–2870

    Article  Google Scholar 

  7. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY (2012) The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost 107:1172–1179

    Article  CAS  PubMed  Google Scholar 

  8. Pisters R, Lande DA, Nieuwlaat R, de Vos CB, Crign JGM, Lip GYH (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138(5):1093–1100

    Article  PubMed  Google Scholar 

  9. Lip GY, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History, or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57:173–180

    Article  CAS  PubMed  Google Scholar 

  10. January CT, Wann S, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 130(23):2071–2104

    Article  PubMed  Google Scholar 

  11. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blactchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206–1214

    Article  CAS  PubMed  Google Scholar 

  12. University Hospital Inselspital. Comparison of antithrombotic treatments after aortic valve replacement. Rivaroxaban: a new antithrombotic treatment for patients with mechanical prosthetic aortic heart valve. In: ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US). 2000–April 2015. https://clinicaltrials.gov/ct2/show/NCT02128841?term=rivaroxaban+mechanical+valve&rank=1. NLM Identifier: NCT02128841

  13. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Maatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S (2011) Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation—an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123:2363–2372

    Article  CAS  PubMed  Google Scholar 

  14. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff L, Hansen ML, Raunso J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C (2011) Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 106:739–749

    Article  CAS  PubMed  Google Scholar 

  15. Mant J, Hobbs FD, Fletcher K, Foalfe A, Fitzmaurice D, Lip GY, Murray E (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 370:493–503

    Article  CAS  PubMed  Google Scholar 

  16. Barnes GD, Kaatz S, Winfield J, Gu X, Haymart B, Kline-Rodgers E, Kozlowski J, Beasley D, Almany S, Leyden T, Froehlich JB (2014) Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). J Thromb Thrombolysis 37:171–176

    Article  CAS  PubMed  Google Scholar 

  17. Rosanio S, Keylani AM, D’Agostino DC, DeLaughter CM, Vitarelli A (2014) Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int J Cardiol 174(3):471–483

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors of this manuscript have no actual or potential conflicts of interest capable of influencing judgment on the part of any author.

Author information

Authors and Affiliations

  1. University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI, 53792, USA

    Jennifer L. Garber, Katie L. Willenborg & Anne E. Rose

Authors
  1. Jennifer L. Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katie L. Willenborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne E. Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer L. Garber.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, J.L., Willenborg, K.L. & Rose, A.E. Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection. J Thromb Thrombolysis 40, 248–254 (2015). https://doi.org/10.1007/s11239-015-1223-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1223-5

Keywords

Search

Navigation